Status:
COMPLETED
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Millennium Pharmaceuticals, Inc.
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
Detailed Description
Subjects on this study will be receiving treatment for multiple myeloma according to the standard of care with a regimen containing Bortezomib. If a bone marrow sample is clinically indicated to guid...
Eligibility Criteria
Inclusion
- Newly diagnosed multiple myeloma
- Therapy with bortezomib alone or bortezomib/dexamethasone being initiated as the standard of care therapy for myeloma by their treating physician
Exclusion
- Hypersensitivity to bortezomib, boron or mannitol
- Treatment with other investigational drugs within 28 days before enrollment
- Diagnosed or treated for another malignancy within 6 months of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
- Use of other myeloma directed therapy (except for dexamethasone) in combination with bortezomib
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01472627
Start Date
October 1 2010
End Date
January 1 2018
Last Update
January 11 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215